COVID-19 is primarily a respiratory disease but up to two thirds of hospitalised patients show
evidence of central nervous system (CNS) damage, predominantly ischaemic, in some …

Accumulating evidence suggests that severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection causes various neurological symptoms in patients with coronavirus …

A wide range of neurological manifestations have been associated with the development of
COVID-19 following SARS-CoV-2 infection. However, the etiology of the neurological …

Neurological symptoms, including cognitive impairment and fatigue, can occur in both the
acute infection phase of coronavirus disease 2019 (COVID-19) and at later stages, yet the …

SARS‐CoV‐2 infection can damage the nervous system with multiple neurological
manifestations described. However, there is limited understanding of the mechanisms …

Background Cognitive deficits are among the main disabling symptoms in COVID-19
patients and post-COVID syndrome (PCS). Within brain regions, the hippocampus, a key …

The main discussion above of the novel pathogenic severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection has focused substantially on the immediate risks and …

The COVID-19 pandemic has posed unique risks to people with Alzheimer disease and
dementia. Research from 2020 has shown that these people have a relatively high risk of …

Introduction Mild cognitive impairment (MCI) is a prodromal stage to dementia, affecting up
to 20% of the aging population worldwide. Patients with MCI have an annual conversion rate …

There are a number of potential implications for the field of Alzheimer's disease (AD)
stemming from the global spread of SARS-CoV-2. Neuroinflammation is known to be a …